Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world. This gives buyers a number of choices for adding investments that will make them money to their accounts.

With only a few weeks left in the year, it’s clear that healthcare stocks are more than just a trend. Because they are strong and last a long time, they are a good purchase.

In 2024, healthcare stocks will once again pique the interest of buyers due to their recognition of the industry’s potential for generating substantial profits.

It’s important to remember that this excitement is based on the big changes that are happening in the healthcare field. Because we can see the shift everywhere, it’s not just an idea. The business is doing well because of new medicines, better technology, and more people living longer. This article talks about the healthcare stocks that are going to go through the roof in 2024. In a business that is always changing, they offer buyers a unique mix of chance and safety. Stay tuned and learn the ins and outs of this very important business.

Vertex Pharmaceuticals (VRTX)

pharmaceutical industry. Production line machine conveyor with glass bottles ampoules at factory

Source: Dmitry Kalinovsky /

Thanks to its inventive steps, Vertex Pharmaceuticals (NASDAQ:VRTX) is making a significant mark in the 2024 healthcare stocks market. Recently, the firm achieved a significant milestone when the FDA approved CASGEVY, a ground-breaking gene treatment for transfusion-dependent beta thalassemia. This approval is not stand-alone; it follows Saudi Arabia’s approval of a comparable medication for sickle cell disease and beta thalassemia. These developments highlight Vertex’s expertise in gene editing and its dedication to treating uncommon genetic illnesses.

Vertex is making great progress in pain treatment in a similar innovative vein. During mid-stage studies, our experimental non-opioid painkiller, VX-548, has effectively exhibited pain reduction in individuals with diabetic peripheral neuropathy. This finding, which offers a potentially addiction-free pain treatment alternative, is especially significant in the current opioid-wary healthcare environment. Analysts predict that VX-548’s market prospects are promising, with yearly sales expected to exceed five billion dollars, with an eye toward mid-2024 for U.S. certification.

These achievements demonstrate Vertex’s strategic growth outside its stronghold in cystic fibrosis. They also demonstrate its transformation into a diverse biopharmaceutical company. Vertex is a major player to watch in the 2024 healthcare stock market as it expands its portfolio. It also maintains its reputation as a leader in innovation in the industry with each invention.

CRISPR Therapeutics (CRSP)

Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech

Source: Image

In 2024, the world of healthcare stocks is always changing. CRISPR Therapeutics (NASDAQ:CRSP) has been in the news for its groundbreaking gene therapy work. Even though the company is facing problems lately, its creative method of changing genes is getting a lot of attention. The market for cell and gene therapy is expected to grow to an amazing $80 billion by 2029. CRISPR Therapeutics is ready to take advantage of this growing area.

But not all news about the company has been good. Concerns were raised when its Chief Medical Officer quit, and TD Cowen said that CRISPR would fail because of an “irrational” value. Still, some experts have raised their expectations for CRISPR because of its diverse pipeline and focus on getting approvals quickly. This shows that they are optimistic about the company’s future.

Investors are still interested in CRISPR’s attempts to make gene-edited treatment exa-cel better, even though recent financials may have shown muted reactions and changes in stock performance. With its one-of-a-kind method and ability to change the whole industry, CRISPR Therapeutics is still one of the most important healthcare stocks to keep an eye on in 2024.

As CRISPR Therapeutics rides the ups and downs of the stock market, its work with Vertex on licensing deals for diabetes treatments and the UK’s approval of its sickle cell gene-editing medicine have made it even more important. The company’s persistence and relationships show that it is dedicated to improving gene editing technologies and meeting important medical needs. This makes it a strong candidate in the constantly changing 2024 healthcare stock market. Investors are still keeping an eye on CRISPR’s progress, looking forward to what the future holds in this rapidly changing field.

Illumina (ILMN)

healthcare stocks: doctors posing. retirement stocks. Healthcare stocks

Source: Shutterstock

Among the many players in the 2024 healthcare stock market, Illumina (NASDAQ:ILMN) is a shining example of innovation. This business has shown incredible dexterity in negotiating the intricate world of genetics and biotechnology. Illumina’s strong dedication to developing healthcare solutions is reflected of most recent financial statements. It has released positive numbers that highlight its tenacity in a cutthroat industry.

Furthermore, Illumina’s strategic alliances are shown by its relationship with Janssen on molecular residual illness cancer testing. These collaborations are essential to expanding the field of medical research. Illumina is more than simply another company in the medical field. Its revolutionary work in genetic sequencing is influencing the direction of customized medicine.

Both industry observers and investors are closely following Illumina’s progress. Changes in its stock price provide an indication of the company’s capacity to impact worldwide healthcare patterns. Illumina solidifies its role as a major player in the healthcare revolution of 2024 with every invention.

On the publication date, Faizan Farooque did not hold (directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the Publishing Guidelines.

Faizan Farooque is a contributing author for and numerous other financial sites. Faizan has several years of experience in analyzing the stock market and was a former data journalist at S&P Global Market Intelligence. His passion is to help the average investor make more informed decisions regarding their portfolio.

You may also like...